New cancer drug combo tested in early human trial
NCT ID NCT04417465
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This early-stage trial tested an experimental drug called ABBV-CLS-579, given alone or combined with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The study aimed to find safe and tolerable doses and check for any signs of tumor shrinkage. Participants received the drug until their disease worsened or they stopped due to side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology Group Springdale
Springdale, Arkansas, 72762, United States
-
Hopital Saint-Andre
Bordeaux, 33000, France
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-Shi, Chiba, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
The Chaim Sheba Medical Center
Ramat Gan, 5262100, Israel
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Wakayama Medical University Hospital
Wakayama, Wakayama, 641-8510, Japan
-
Yale University
New Haven, Connecticut, 06519, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-CLS-579 (oral capsule), PD-1 inhibitor (intravenous infusion), and VEGFR TKI (oral tablet)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial, so the main goals are safety and dosing, not yet proving effectiveness. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.